Most Read Articles
27 Nov 2017
The amino sulphonic acid taurine may safely and effectively reduce portal pressure in cirrhotic patients, a study has shown.
Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
Audrey Abella, 23 Jan 2019
A single infusion of the monoclonal antibody rituximab temporarily delays the clinical onset of rheumatoid arthritis (RA) through B-cell depletion, underpinning the preventive potential of rituximab in RA development especially in high-risk individuals, according to the PRAIRI* study.
26 Nov 2019
Podcast: Professor R. Scott Wright speaks about the potential role of inclisiran in providing durable reductions in LDL-cholesterol levels in patients with atherosclerotic cardiovascular disease.

Add-on curcumin nanomicelle beneficial in rheumatoid arthritis treatment

04 Oct 2019

The addition of curcumin nanomicelle to the treatment regimen of patients with rheumatoid arthritis (RA) positively influences several outcomes, although not meaningfully, as shown in a trial.

A total of 65 RA patients were randomized to receive either a curcumin nanomicelle 40 mg (n=30) or placebo (n=35) capsule three times a day for 12 weeks. Researchers measured the Disease Activity Score of 28 joints (DAS‐28) and erythrocyte sedimentation rate (ESR) at baseline and after 12 weeks.

Results showed that DAS‐28, tender joint count (TJC) and swollen joint count (SJC) improved substantially from baseline at the end of treatment in both the curcumin and placebo groups. There were no significant between-group differences seen in the magnitude of change, as well as in baseline values. Nonetheless, the improvements were numerically greater in the active treatment group.

No significant changes were documented in ESR between the two treatment groups.

A major extraction derived from turmeric, curcumin possesses excellent antitumour, antimicrobial and antioxidant properties. However, the substance has poor bioavailability owing to its poor solubility, poor absorption, rapid metabolism and quick systemic elimination, all of which limits its therapeutic effect in vivo. To resolve these limitations, various nanomicelles have been used to construct a protective structure, which works both to prolong its circulation inside the body and to enhance its solubility. [ACS Appl Mater Interfaces 2018;10:23595-23604]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
27 Nov 2017
The amino sulphonic acid taurine may safely and effectively reduce portal pressure in cirrhotic patients, a study has shown.
Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
Audrey Abella, 23 Jan 2019
A single infusion of the monoclonal antibody rituximab temporarily delays the clinical onset of rheumatoid arthritis (RA) through B-cell depletion, underpinning the preventive potential of rituximab in RA development especially in high-risk individuals, according to the PRAIRI* study.
26 Nov 2019
Podcast: Professor R. Scott Wright speaks about the potential role of inclisiran in providing durable reductions in LDL-cholesterol levels in patients with atherosclerotic cardiovascular disease.